TrialThe international journal of neuropsychopharmacology2023

Phase 2 Results Indicate Evenamide, A Selective Modulator of Glutamate Release, Is Associated With Clinically Important Long-Term Efficacy When Added to an Antipsychotic in Patients With Treatment-Resistant Schizophrenia.

Ravi Anand et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.